Using Explicit Thresholds were valuable for judging Benefits and Harms in partially contextualized GRADE Guidelines.

COVID-19 Clinical guidelines GRADE

Journal

Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383

Informations de publication

Date de publication:
07 2022
Historique:
received: 17 06 2021
revised: 11 03 2022
accepted: 21 03 2022
pubmed: 2 4 2022
medline: 12 10 2022
entrez: 1 4 2022
Statut: ppublish

Résumé

Guideline panels must assess the magnitude of health benefits and harms to develop sensible recommendations. However, they rarely use explicit thresholds. In this paper we report on the piloting and the use thresholds for benefits and harms. We piloted the use of thresholds in a Chilean COVID-19 living guideline. For each of the critical outcomes, we asked panelists to suggest values of the thresholds for large, moderate, small, or trivial or no effect. We collected this information through a survey and an on-line discussion. Twelve panelists decided on thresholds for three critical outcomes (mortality, need for mechanical ventilation and serious adverse events). For all outcomes, an absolute risk reduction was considered larger with more than 50 events, moderate with less than 50 events, small with less than 25 events, and trivial with less than 10 events. Having these a priori thresholds in place significantly impacted on the development of recommendations. Explicit thresholds were a valuable addition to the judgment of the certainty in the evidence, to decide the direction and strength of the recommendation and to evaluate the need for update. We believe this is a line of research worth perusing.

Identifiants

pubmed: 35364230
pii: S0895-4356(22)00078-6
doi: 10.1016/j.jclinepi.2022.03.017
pmc: PMC8963975
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-75

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
Ann Med Surg (Lond). 2021 Apr;64:102204
pubmed: 33692899
Blood Adv. 2020 Mar 10;4(5):953-968
pubmed: 32150612
BMJ. 2016 Jun 30;353:i2089
pubmed: 27365494
BMJ Open. 2019 Jun 4;9(6):e027445
pubmed: 31167868
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
BMJ Open. 2022 Mar 10;12(3):e053246
pubmed: 35273045
J Clin Epidemiol. 2017 Jul;87:4-13
pubmed: 28529184

Auteurs

Ignacio Neumann (I)

Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile; Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. Electronic address: Ignacio.neumann@gmail.com.

Eduardo Quiñelen (E)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Paula Nahuelhual (P)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Pamela Burdiles (P)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Natalia Celedón (N)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Katherine Cerda (K)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Paloma Herrera-Omegna (P)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Patricia Kraemer (P)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Karen Dominguez Cancino (KD)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Escuela de Enfermería, Universidad Científica del Sur, Lima, Peru.

Juan Pablo Valenzuela (JP)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Dino Sepúlveda (D)

Department of Health Technology Assessments, Ministerio de Salud de Chile, Santiago, Chile.

Gian Paolo Morgano (GP)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Elie A Akl (EA)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Holger J Schünemann (HJ)

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH